ALK(SZ:002940) He Xun Wang·2025-07-01 14:30Core Viewpoint - On July 1, 2023, Anglikon (002940) reached a historical high in stock price and issued a warning regarding the risks associated with its innovative drug development, highlighting the long, costly, and uncertain nature of the process [1] Group 1: Company Performance and Stock Movement - Anglikon has only one innovative drug project, ALK-N001, currently in Phase I clinical trials, with approval expected by April 2025 [1] - The stock price of Anglikon closed at 40.82 CNY per share, with a trading volume of 6.18 billion CNY and a market capitalization of 82.35 billion CNY [1] - The company experienced a net profit decline of 42% last year and a 43.63% drop in the first quarter of this year, attributed to increased R&D expenses [1] Group 2: Market and Policy Impact - The innovative drug sector saw a surge due to favorable policies, including the inclusion of innovative drugs in the basic medical insurance catalog and the establishment of new payment channels [1] - Other innovative drug stocks also performed well, with Frontier Bio hitting a 20% limit up, Kexing Pharmaceutical rising over 17%, and Shutaishen increasing over 13% [1] - Anglikon's stock has increased by 182% in the first half of the year, with a 146.41% rise in June alone, driven by institutional investments [1] Group 3: R&D Investment - Anglikon's R&D expenses reached 231 million CNY, a 33.74% increase year-on-year, accounting for 14.99% of its revenue [1] - The increase in R&D investment is part of the company's strategy to transition towards innovative drugs, collaborating with Qinhuli to develop ALK-N001/QHL-1618 [1]